CHRONIC MYELOID-LEUKEMIA TREATMENT WITH R ECOMBINANT INTERFERON-ALPHA-2

A trial has been conducted of recombinant alpha2-interferon (reaferon) used in 32 patients with Rh'-positive chronic myeloid leukemia (CML). A chronic stage was in 3, transient in 3 and blast in 1 patients. 25 CML patients were newly diagnosed. The treatment lasted from 2 months to 3 years. Clinicohematological remission was confirmed conventionall y and by the degree of Ph'-positive clone reduction. An attempt is mad e to clarify the mechanism underlying the resistance of reaferon basin g on the immunological data (detection of antireaferon neutrolizing an tibodies). The authors propose of combined treatment (myelosan plus re aferon) of CML which has obvious advantages over myelosan monotherapy.